Acute and Maintenance Treatment for Focal Seizures
For acute focal seizures, administer benzodiazepines first-line (lorazepam IV or midazolam IM/buccal/intranasal), followed immediately by levetiracetam, fosphenytoin, or valproate as second-line agents if seizures persist beyond 5 minutes—all three have equivalent efficacy. For maintenance therapy, start carbamazepine or lamotrigine as first-line monotherapy, with levetiracetam as an equally effective alternative.
Acute Management Algorithm
First-Line Treatment (0-5 minutes)
- Benzodiazepines are mandatory initial therapy 1
- IV access available: Lorazepam IV (preferred) or diazepam IV
- No IV access: Midazolam IM (best evidence), or buccal/intranasal midazolam 2
- These medications prevent progression to status epilepticus, defined as seizures lasting >5 minutes
Second-Line Treatment (5-20 minutes)
If seizures continue despite adequate benzodiazepine dosing, immediately administer one of three equally effective agents 1:
Levetiracetam IV (preferred for safety profile)
- Efficacy: 47% seizure cessation at 60 minutes
- Lowest hypotension risk (0.7%)
- Lowest arrhythmia risk (0.7%)
- Intubation rate: 20%
Fosphenytoin IV
- Efficacy: 45% seizure cessation at 60 minutes
- Hypotension risk: 3.2%
- Intubation rate: 26.4%
- Caution: Risk of arrhythmias, hypotension, extravasation injury, drug interactions
Valproate IV
- Efficacy: 46% seizure cessation at 60 minutes
- Hypotension risk: 1.6%
- Intubation rate: 16.8%
- Rapid loading possible with fewer acute side effects than phenytoin
Critical Point: The ESETT trial demonstrated no statistical difference in efficacy among these three agents 1. Choose based on patient-specific factors (cardiac history, drug interactions, pregnancy status).
Refractory Status Epilepticus (>20-40 minutes)
- If second-line agents fail, consider lacosamide or additional AEDs 3, 4
- Delay anesthetic drugs as long as safely possible in focal SE 4—unlike generalized convulsive SE, focal motor SE may not require immediate anesthesia
- Continuous EEG monitoring is essential to detect non-convulsive status epilepticus 2
Maintenance Therapy
First-Line Monotherapy Options
For focal seizures, carbamazepine and lamotrigine are guideline-recommended first-line treatments, with levetiracetam showing equivalent efficacy 5, 6:
Lamotrigine (optimal choice for treatment retention)
- Superior treatment continuation rates compared to most other AEDs
- Lower treatment failure rates than carbamazepine (HR 1.26,95% CI 1.10-1.44) 5
- Fewer adverse events leading to discontinuation
- Caution: Requires slow titration to avoid Stevens-Johnson syndrome
Carbamazepine (traditional first-line)
- Extensive evidence base
- Better time to first seizure than newer agents 5
- Caution: Drug interactions via CYP450 induction, hyponatremia risk, rash potential
Levetiracetam (increasingly preferred alternative)
- No significant difference from lamotrigine for treatment failure 5
- Rapid titration possible
- Minimal drug interactions
- Better tolerability profile than carbamazepine
- Caution: Psychiatric side effects (irritability, depression)
Alternative Monotherapy Options
If first-line agents fail or are contraindicated 5, 7:
- Oxcarbazepine: Fewer drug interactions than carbamazepine, similar efficacy
- Zonisamide: Comparable efficacy to lamotrigine
- Lacosamide: Lower discontinuation rates due to adverse events than carbamazepine (OR 0.659,95% CI 0.428-0.950) 7
- Eslicarbazepine acetate: Non-inferior to carbamazepine
When to Start Maintenance Therapy
- Initiate after a second unprovoked focal seizure 6
- Consider after first seizure if high recurrence risk (structural lesion, abnormal EEG, nocturnal seizure)
Critical Pitfalls to Avoid
Do NOT prescribe benzodiazepines or ASMs for functional (psychogenic non-epileptic) seizures 8—confirm diagnosis with video-EEG before long-term treatment
Do NOT delay second-line treatment in status epilepticus—every minute increases morbidity and mortality 2
Do NOT assume seizure cessation means treatment success—transition to non-convulsive SE is common; obtain EEG if patient not fully awake 2
Do NOT use phenytoin as first choice when alternatives available—higher adverse event profile than levetiracetam or valproate 1
Do NOT treat focal motor SE as aggressively as generalized convulsive SE—anesthetic drugs should be delayed when possible 4
Monitoring and Follow-up
- Acute setting: Continuous EEG for ≥24 hours if patient not fully awake after seizure control 2
- Maintenance: Monitor for adverse events (drowsiness, headache, GI disturbances, dizziness, rash) 5
- Drug levels: Generally not needed for newer AEDs (levetiracetam, lamotrigine, lacosamide); may be useful for carbamazepine, phenytoin, valproate